The use of an Eli Lilly & Co. (LLY) chemotherapy drug after surgery for pancreatic cancer delayed recurrence of the disease in a patient trial, researchers reported. The study’s results, to be published in the Jan. 17 issue of the Journal of the American Medical Association, could support wider use of Gemzar, which has been the standard treatment for people with advanced pancreatic cancer. Cancer of the pancreas is one of the deadliest forms of the disease, with fewer than 5% of newly diagnosed patients living at least five years. >>> Discuss This Story
